Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis

J Gastrointestin Liver Dis. 2015 Sep;24(3):274. doi: 10.15403/jgld.2014.1121.243.bwp.

Authors

Poonam Beniwal-Patel¹, Kristina Matkowskyj², Freddy Caldera³

Affiliations

¹ Department of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. pbeniwal-patel@uwhealth.org.
² Department of Pathology and Laboratory Medicine, University of Wisconsin Hospital and Clinics, Madison, WI, USA.
³ Department of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

PMID: 26405697
DOI: 10.15403/jgld.2014.1121.243.bwp

No abstract available

Publication types

Case Reports

MeSH terms

Adrenal Cortex Hormones / therapeutic use*
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents / adverse effects*
Biopsy
Colitis / chemically induced
Colitis / diagnosis
Colitis / drug therapy*
Colonoscopy
Drug Resistance*
Humans
Infliximab / therapeutic use*
Ipilimumab
Male
Melanoma / drug therapy*
Melanoma / pathology
Middle Aged
Remission Induction
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Treatment Outcome

Substances

Adrenal Cortex Hormones
Anti-Inflammatory Agents
Antibodies, Monoclonal
Antineoplastic Agents
Ipilimumab
Infliximab